« Previous
Next »
Titles
- Alternative procedures for blood and blood components during the COVID-19 public health emergency1
- Compliance policy regarding blood and blood component donation suitability, donor eligibility and source plasma quarantine hold requirements: guidance for industry1
- Excerpt from Henry Swan's talk at Denver's Red Cross Blood Donor Center1
- Further testing of donations that are reactive on a licensed donor screening test for antibodies to hepatitis C virus1
- Implementation of acceptable full-length and abbreviated donor history questionnaires and accompanying materials for use in screening donors of blood and blood components: guidance for industry1
- Investigational COVID-19 convalescent plasma1
- Nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry1
- Recommendations for evaluating donor eligibility using individual risk-based questions to reduce the risk of human immunodeficiency virus transmission by blood and blood products: guidance for industry1
- Recommendations to reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood components1
- Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components1
- Revised recommendations for reducing the risk of human immunodeficiency virus transmission by blood and blood products1
- Revised recommendations to reduce the risk of transfusion-transmitted malaria1
- Use of serological tests to reduce the risk of transmission of Trypanosoma cruzi infection in blood and blood components1